Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Treatments for HIV-visceral leishmaniasis co-infected patients

06.10.2014

Phase III clinical study in Ethiopia launched to test 2 treatments for HIV-visceral leishmaniasis co-infected patients

The international research & development (R&D) consortium, AfriCoLeish, formed by six research organizations from East Africa and Europe, has launched a Phase III clinical study to address the extreme difficulty in treating visceral leishmaniasis (VL) in patients who also are HIV-positive.


Migrant workers are one of the highly vulnerable, HIV-VL (visceral leishmaniasis) most-affected populations.

Credit: @ Don Paul-DNDi

The study will assess the efficacy and the safety of two treatments: a combination treatment of AmBisome® and miltefosine, and AmBisome® alone. This is the first randomized clinical trial in Africa to confirm the World Health Organization's recommendation for HIV-VL treatment. Two sites, Gondar and Abdurafi, in northwest Ethiopia, one of the highest burden areas in the world, have begun recruiting patients.

HIV-AIDS and VL, fatal without treatment, both affect the immune system of the patients. When the two diseases occur together, treatment of both diseases becomes more challenging. The risk of death from VL is nine times higher in patients who are co-infected with HIV. VL also accelerates the progression of HIV. Relapses of VL in patients co-infected with HIV are also very common, affecting half of treated patients within a year of initial treatment, and overall VL cure rates are significantly lower.

An emerging global problem, VL-HIV cases are reported in 35 countries worldwide, spanning Southern Europe, East Africa, the Indian subcontinent, and Latin America. One of the hardest hit areas in Africa is northwest Ethiopia, where anywhere from 20% to 40% of patients with VL were found to be also infected with HIV.

'Treating patients that suffer both HIV and visceral leishmaniasis is a real battle for clinicians. Research strongly suggests that we need to strike the right balance between stronger treatments and safer treatments', said Koert Ritmeijer, PhD, Health Advisor, Médecins Sans Frontières.

'Combining better initial cure treatments and preventing relapses will be a major step forward for our patients, who today fear that the diseases, which can be managed when they occur separately, often become a death sentence when they occur together. We have to do all we can to provide the most affected, a highly vulnerable migrant population, with an appropriate response', said Dr Ermias Diro, Principal Site Investigator, University of Gondar.

The Phase III clinical study conducted in Gondar and Abdurafi, Ethiopia, will assess the efficacy and safety of the combination of AmBisome® (30mg/kg total dose) and miltefosine (50mg or 100mg/day depending on the patient's weight), and AmBisome® alone (40mg/kg total dose). Total treatment duration is 28 days, if the tests show that the patient is parasite-negative (at day 29). Thereafter, the patient will start a secondary prophylaxis treatment aimed at preventing VL relapses and a one-year follow-up phase. A total of 132 patients will be recruited for the trial.

'Visceral leishmaniasis, notably in East Africa, is among the most neglected of all neglected tropical diseases. The work of this consortium to address the additional challenge of co-infection with HIV in Ethiopia is vital as it has begun to tackle one of the most challenging endemic areas and aspects of this fatal disease', said Dr Jorge Alvar, Head of Leishmanisis Programme, DNDi.

This clinical trial is conducted by DNDi (sponsor) in collaboration with MSF-Holland (co-sponsor); the University of Gondar (UoG), Ethiopia; the Institute of Tropical Medicine (ITM) Antwerp, Belgium; the London School of Hygiene & Tropical Medicine, UK; and is funded by the European Union (EU FP7); the Swiss Agency for Development and Cooperation (SDC), Switzerland; Médecins Sans Frontières; the Federal Ministry of Education and Research (BMBF) through KfW, Germany; the Medicor Foundation, Liechtenstein; and other private donors.

About the study:

  • Overall objective: identify a safe and effective treatment for VL in HIV co-infected patients 

     

  • Study design: a randomized, parallel arm, open-label clinical study

     

     

  • Treatment dosing schedule:
    • AmBisome® monotherapy: 40mg/kg total dose: intravenous infusion 5mg/kg on day 1-5, 10, 17, 24
    • AmBisome®: 30mg/kg total dose: intravenous infusion 5mg/kg on day 1, 3, 5, 7, 9, 11 and miltefosine: every day for 28 days, with 50mg/day (for patient weighting ≤ 25 kg) and 100 mg/day (for patient weighting > 25 kg)

     

     

  • Study duration:
    • Treatment duration is 28 days or 56 days in case of extended treatment (if tissue aspirate is parasite positive at day 29 and the patient is well). When the patients are tested parasite negative, they are eligible for a secondary prophylaxis – pentamidine 4mg/kg intramuscular injection or intravenous infusion once a month – and enter a one-year follow-up phase. At any stage as of day 29, if the patients are unwell, they receive a rescue therapy.

     

     

  • AmBisome® supply for the study is donated by Gilead. Pentamidine supply for the study is donated by Sanofi.

     

About visceral leishmaniasis (VL or kala-azar)

Visceral leishmaniasis is a neglected tropical disease caused by Leishmania donovani or L. infantum. There are an estimated 300,000 new cases of VL per annum. Fatal if left untreated, the disease approximately kills 40,000 people every year. 90% of cases occur in Sudan, Ethiopia, Kenya, Bangladesh, India, Nepal, and Brazil. VL is characterized by prolonged fever and splenomegaly. The current VL therapies administered include pentavalent antimonials [sodium stibogluconate (SSG) and meglumine antimoniate], AmBisome®, miltefosine, and paromomycin (PM).

About AfriCoLeish: http://www.africoleish.org

A research and development (R&D) international consortium, AfriCoLeish is supported by the European Union Seventh Framework Programme (EU FP7) through a grant of €3 million. The project aims to test new treatments for visceral leishmaniasis (VL or kala-azar) in East Africa and co-infection of the disease with HIV in Ethiopia. AfriCoLeish brings together six organizations from Europe and East Africa with vast experience in R&D and treatment of HIV and kala-azar, namely:

Press contact:

Renee Olende, Regional Communications Manager, DNDi Africa
Mobile: +254 705 639 909 / E-mail: rolende@dndi.org

Violaine Dällenbach | Eurek Alert!

Further reports about: HIV Medicine Tropical Medicine diseases intravenous parasite visceral leishmaniasis

More articles from Life Sciences:

nachricht NYSCF researchers develop novel bioengineering technique for personalized bone grafts
18.07.2018 | New York Stem Cell Foundation

nachricht Pollen taxi for bacteria
18.07.2018 | Technische Universität München

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: First evidence on the source of extragalactic particles

For the first time ever, scientists have determined the cosmic origin of highest-energy neutrinos. A research group led by IceCube scientist Elisa Resconi, spokesperson of the Collaborative Research Center SFB1258 at the Technical University of Munich (TUM), provides an important piece of evidence that the particles detected by the IceCube neutrino telescope at the South Pole originate from a galaxy four billion light-years away from Earth.

To rule out other origins with certainty, the team led by neutrino physicist Elisa Resconi from the Technical University of Munich and multi-wavelength...

Im Focus: Magnetic vortices: Two independent magnetic skyrmion phases discovered in a single material

For the first time a team of researchers have discovered two different phases of magnetic skyrmions in a single material. Physicists of the Technical Universities of Munich and Dresden and the University of Cologne can now better study and understand the properties of these magnetic structures, which are important for both basic research and applications.

Whirlpools are an everyday experience in a bath tub: When the water is drained a circular vortex is formed. Typically, such whirls are rather stable. Similar...

Im Focus: Breaking the bond: To take part or not?

Physicists working with Roland Wester at the University of Innsbruck have investigated if and how chemical reactions can be influenced by targeted vibrational excitation of the reactants. They were able to demonstrate that excitation with a laser beam does not affect the efficiency of a chemical exchange reaction and that the excited molecular group acts only as a spectator in the reaction.

A frequently used reaction in organic chemistry is nucleophilic substitution. It plays, for example, an important role in in the synthesis of new chemical...

Im Focus: New 2D Spectroscopy Methods

Optical spectroscopy allows investigating the energy structure and dynamic properties of complex quantum systems. Researchers from the University of Würzburg present two new approaches of coherent two-dimensional spectroscopy.

"Put an excitation into the system and observe how it evolves." According to physicist Professor Tobias Brixner, this is the credo of optical spectroscopy....

Im Focus: Chemical reactions in the light of ultrashort X-ray pulses from free-electron lasers

Ultra-short, high-intensity X-ray flashes open the door to the foundations of chemical reactions. Free-electron lasers generate these kinds of pulses, but there is a catch: the pulses vary in duration and energy. An international research team has now presented a solution: Using a ring of 16 detectors and a circularly polarized laser beam, they can determine both factors with attosecond accuracy.

Free-electron lasers (FELs) generate extremely short and intense X-ray flashes. Researchers can use these flashes to resolve structures with diameters on the...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Leading experts in Diabetes, Metabolism and Biomedical Engineering discuss Precision Medicine

13.07.2018 | Event News

Conference on Laser Polishing – LaP: Fine Tuning for Surfaces

12.07.2018 | Event News

11th European Wood-based Panel Symposium 2018: Meeting point for the wood-based materials industry

03.07.2018 | Event News

 
Latest News

NYSCF researchers develop novel bioengineering technique for personalized bone grafts

18.07.2018 | Life Sciences

Machine-learning predicted a superhard and high-energy-density tungsten nitride

18.07.2018 | Materials Sciences

Why might reading make myopic?

18.07.2018 | Health and Medicine

VideoLinks
Science & Research
Overview of more VideoLinks >>>